Personalized GLP1 use in Maryland
GLP-1 Agonists and Pancreatitis Risk: Reassessing an Old Concern with New Evidence
Modern data confirm GLP-1 agonists are not linked to pancreatitis. Studies from 2025 show no increase in risk and, in some cases, lower recurrence rates and mortality. These findings overturn old concerns and highlight how improved metabolic control may protect the pancreas. Clinicians can now use GLP-1s more confidently as part of holistic, individualized care for diabetes and obesity.
Published
Categorized as Dr. Tashko’s Key Clinical Trials, GLP1 agonist, Insights from Dr. Tashko, Pancreas Health
Oral Semaglutide 25 mg and Orforglipron for Obesity: New NEJM Insights
Three new NEJM trials highlight the potential of oral GLP-1 therapies for obesity and diabetes. Oral semaglutide 25 mg and orforglipron both achieved double-digit weight loss, far greater than Rybelsus 14 mg. Results from the OASIS-4, ATTAIN-1, and ACHIEVE-1 studies suggest next-generation oral medications may soon rival injectables. These may give patients more flexible, effective, and convenient options for long-term weight management and metabolic health.
Published
MariTide vs Tirzepatide: Similarities and Differences
MariTide and tirzepatide are changing obesity treatment. Both target gut hormones to support weight loss, yet they act differently. Tirzepatide is already approved as a weekly injection, while MariTide is still in trials as a monthly option. Patients may soon have more tailored choices for appetite control and metabolic health.
Published
Once-Monthly MariTide Shows Promise for Weight Loss
MariTide, a once-monthly obesity treatment studied in NEJM, achieved 12–16% weight loss in participants without diabetes and up to 12% in those with diabetes. Patients also saw lower blood sugar levels. Side effects were mostly gastrointestinal and improved with dose escalation. At our Maryland practice, we offer comprehensive obesity and diabetes care, helping patients explore advanced therapies with a balanced viewpoint and personalized care.
Published
Adjusting Your Insulin Pump When Starting a GLP-1 Medication
Starting a GLP-1 medication like Mounjaro or Ozempic? If you use an insulin pump, you may need to adjust your settings. GLP-1s can reduce blood sugar spikes and meal size, making previous doses too strong. Learn how to modify your carb ratio, correction factor, and basal rate to stay safe.
Published
GLP-1 Agonists and Heart Rate: Prevalence and Clinical Significance
GLP-1 agonists like tirzepatide and semaglutide often raise resting heart rate by a few beats per minute. While this is common and usually mild, it may matter in patients with heart rhythm issues, heart failure, or high baseline pulse. This blog explores why it happens, who’s at risk, and how to manage it thoughtfully in clinical care.
Published